AstraZeneca (AZN) – Investment Analysts’ Recent Ratings Updates

AstraZeneca (LON: AZN) has recently received a number of price target changes and ratings updates:

• 1/16/2026 – AstraZeneca had its “buy” rating reaffirmed by analysts at Shore Capital.
• 1/15/2026 – AstraZeneca had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from £105 to £110. They now have a “sell” rating on the stock.
• 1/15/2026 – AstraZeneca had its “overweight” rating reaffirmed by analysts at JPMorgan Chase & Co..
• 1/6/2026 – AstraZeneca had its “overweight” rating reaffirmed by analysts at JPMorgan Chase & Co..
• 12/4/2025 – AstraZeneca had its “overweight” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a £140 price target on the stock.

Insider Buying and Selling at AstraZeneca

In related news, insider Nazneen Rahman sold 297 shares of AstraZeneca stock in a transaction on Thursday, December 18th. The stock was sold at an average price of £134.96, for a total transaction of £40,083.12. 0.14% of the stock is currently owned by company insiders.

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.